EUVIMEDAtklāt EUVIMED
Multizentrische StudieOpen access · CC BY-NC 4.0

A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 2021

Jeremy W Jacobs iD, Brian D Adkins iD, Garrett S Booth iD, Caroline G Stanek iD, Elizabeth S Allen, Brenda J Grossman iD, Laura D Stephens iD, Elizabeth P Crowe iD, Laetitia Daou, Marisa B Marques iD, Rance C Siniard, Lisa R Wallace and 23 more

Journal of Clinical Apheresis · 2025

DOI: 10.1002/jca.70017 ↗

At a glance

Multizentrische Studie in Journal of Clinical Apheresis, 2025. Written by Jeremy W Jacobs and 34 co-authors. Institution: Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Major MEDLINE topics: Purpura, Thrombotic Thrombocytopenic, Blood Component Removal. Cited 3 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NHLBI NIH HHS, National Heart Lung and Blood Institute, National Heart, Lung, and Blood Institute.

AbstraktsSubjectsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

Immune thrombotic thrombocytopenic purpura (iTTP) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion secondary to acquired ADAMTS13 deficiency. Contemporary data regarding iTTP treatment practices in the US, including the use of caplacizumab, are lacking. We aimed to characterize the demographics and therapies, including medications and apheresis practices, in patients with iTTP in the US. We retrospectively analyzed iTTP cases at 15 sites in the US that provide comprehensive care for patients with iTTP. The time‐period assessed was from January 1, 2017 to December 31, 2021. Our primary objective was to analyze data by iTTP episode, inclusive of initial episodes and relapses. A total of 390 iTTP episodes were reported for 280 unique individuals (187 females, 93 males). Thirty‐day mortality was 3.7% (14/374), and 6‐month mortality was 7.4% (27/367). TPE details were reported for 343 episodes, among which 261 underwent at least one procedure (median 6, IQR 3–11). Among the 261 episodes with at least one therapeutic plasma exchange (TPE) performed, 82.0% (214/261) used only plasma. Caplacizumab was used either alone or in combination with other agents in 43 (11.0%) episodes. Management strategies for iTTP remain varied across centers in the US, with a variety of combinations for TPE replacement fluids and therapeutic agents, as well as limited use of caplacizumab. Further research and standardization of treatment regimens may further reduce mortality in this condition.

Subjects

MeSH terms (MEDLINE)

Purpura, Thrombotic ThrombocytopenicBlood Component RemovalHumansFemaleMaleRetrospective StudiesUnited StatesMiddle AgedAdultAgedPlasma ExchangeADAMTS13 ProteinYoung AdultAdolescentSingle-Domain Antibodies

Author keywords

apheresiscaplacizumabepidemiologyhematologytherapeutic plasma exchangethrombotic thrombocytopenic purpuratransfusion medicine

Substances

caplacizumabADAMTS13 ProteinADAMTS13 protein, humanSingle-Domain Antibodies

Authors and institutions

  • Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Division of Transfusion Medicine and Hemostasis, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Department of Pathology, University of California San Diego, La Jolla, California, USA.
  • Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID profiles: Jeremy W Jacobs, Brian D Adkins, Garrett S Booth, Caroline G Stanek, Brenda J Grossman, Laura D Stephens, Elizabeth P Crowe, Marisa B Marques, Chisa Yamada, Justin E Juskewitch, Ingrid Perez-Alvarez, Meredith G Parsons, Annette J Schlueter, Christopher A Tormey, Sean G Yates, Evan M Bloch, Jay S Raval

Funding

  • NHLBI NIH HHS
  • National Heart Lung and Blood Institute
  • National Heart, Lung, and Blood Institute

Cite

APA

Jacobs, J. W., Adkins, B. D., Booth, G. S., Stanek, C. G., Allen, E. S., Grossman, B. J., Stephens, L. D., Crowe, E. P., Daou, L., Marques, M. B., Siniard, R. C., Wallace, L. R., Yamada, C., Duque, M. A., Wu, Y., Aljuboori, O., Harrington, T. J., Byrnes, D. M., Eichbaum, Q., …, & Raval, J. S. (2025). A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 2021. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70017

Vancouver

Jacobs JW, Adkins BD, Booth GS, Stanek CG, Allen ES, Grossman BJ, et al. A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 2021. Journal of Clinical Apheresis. 2025. doi:10.1002/jca.70017

BibTeX
@article{Jacobs2025,
  author = {Jacobs, Jeremy W and Adkins, Brian D and Booth, Garrett S and Stanek, Caroline G and Allen, Elizabeth S and Grossman, Brenda J and Stephens, Laura D and Crowe, Elizabeth P and Daou, Laetitia and Marques, Marisa B and Siniard, Rance C and Wallace, Lisa R and Yamada, Chisa and Duque, Miriam Andrea and Wu, Yanyun and Aljuboori, Omar and Harrington, Thomas J and Byrnes, Diana M and Eichbaum, Quentin and Figueroa Villalba, Cristina A and Juskewitch, Justin E and Klapper, Ellen and Perez-Alvarez, Ingrid and Klein, Monica S and Aldarweesh, Fatima and Alkhateb, Rahaf and Parsons, Meredith G and Schlueter, Annette J and Tormey, Christopher A and Wheeler, Allison P and Powers, Amy A and Webb, Christopher B and Yates, Sean G and Bloch, Evan M and Raval, Jay S},
  title = {A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 2021},
  journal = {Journal of Clinical Apheresis},
  year = {2025},
  doi = {10.1002/jca.70017}
}
Start for free →